Active	Status	Sponsor type	Region	Phase	Filter
8 Active 15 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
dexpramipexole (KNS-760704) / Areteia Therapeutics
2022-003004-33: Assess the efficacy, safety, & tolerability of oral dexpramipexole in severe eosinophilic asthma	Not yet recruiting	3	1395	Europe	Dexpramipexole 75mg, Dexpramipexole 150mg, KNS-760704, Film-coated tablet	Areteia Therapeutics, Inc., Areteia Therapeutics, Inc.	Severe Eosinophilic Asthma, Severe Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
2022-003005-30: Eosinophilic asthma	Ongoing	3	550	Europe	Dexpramipexole 75mg, Dexpramipexole 150mg, KNS-760704, Film-coated tablet	Areteia Therapeutics, Inc., Areteia Therapeutics, Inc.	Eosinophilic Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
EXHALE-4, NCT05748600 / 2022-003005-30: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma	Active, not recruiting	3	600	Europe, Canada, US, RoW	Dexpramipexole Dihydrochloride, Placebo	Areteia Therapeutics, Areteia Therapeutics, Inc.	Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack	09/25	12/25
EXHALE-5, NCT06388889: Phase III Long-Term Extension Study With Dexpramipexole	Enrolling by invitation	3	1600	Europe, US, RoW	Dexpramipexole Dihydrochloride	Areteia Therapeutics	Eosinophilic Asthma	03/28	05/28
EXHALE-2, NCT05763121 / 2022-003004-33: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.	Recruiting	3	1395	Europe, Canada, Japan, US, RoW	Dexpramipexole Dihydrochloride, Placebo	Areteia Therapeutics, Areteia Therapeutics, Inc.	Eosinophilic Asthma, Asthma; Eosinophilic, Asthma	03/27	05/27
EXHALE-3, NCT05813288: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma	Recruiting	3	930	Europe, Japan, US, RoW	Dexpramipexole Dihydrochloride, Placebo	Areteia Therapeutics	Eosinophilic Asthma, Asthma; Eosinophilic, Asthma	12/26	02/27
2019-003013-34: Targeting severe asthma sub-types with a view to reducing worsening symptoms, improving asthma control, quality of life and lung function.	Not yet recruiting	2	234	Europe	Dexpramipexole, Vibrox, KNS-760704, Tablet, Capsule, Vibrox	University of Leicester, National Institute for Health Research, EME, Knopp Biosciences LLC	T2-High and T2-Low severe asthma, Sub-types of severe asthma, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
SUSPIRE-1, NCT06533553: A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD	Active, not recruiting	2	30	US	Dexpramipexole Dihydrochloride	Areteia Therapeutics	Chronic Obstructive Pulmonary Disease	10/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
dexpramipexole (KNS-760704) / Areteia Therapeutics
2022-003004-33: Assess the efficacy, safety, & tolerability of oral dexpramipexole in severe eosinophilic asthma	Not yet recruiting	3	1395	Europe	Dexpramipexole 75mg, Dexpramipexole 150mg, KNS-760704, Film-coated tablet	Areteia Therapeutics, Inc., Areteia Therapeutics, Inc.	Severe Eosinophilic Asthma, Severe Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
2022-003005-30: Eosinophilic asthma	Ongoing	3	550	Europe	Dexpramipexole 75mg, Dexpramipexole 150mg, KNS-760704, Film-coated tablet	Areteia Therapeutics, Inc., Areteia Therapeutics, Inc.	Eosinophilic Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
EXHALE-4, NCT05748600 / 2022-003005-30: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma	Active, not recruiting	3	600	Europe, Canada, US, RoW	Dexpramipexole Dihydrochloride, Placebo	Areteia Therapeutics, Areteia Therapeutics, Inc.	Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack	09/25	12/25
EXHALE-5, NCT06388889: Phase III Long-Term Extension Study With Dexpramipexole	Enrolling by invitation	3	1600	Europe, US, RoW	Dexpramipexole Dihydrochloride	Areteia Therapeutics	Eosinophilic Asthma	03/28	05/28
EXHALE-2, NCT05763121 / 2022-003004-33: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.	Recruiting	3	1395	Europe, Canada, Japan, US, RoW	Dexpramipexole Dihydrochloride, Placebo	Areteia Therapeutics, Areteia Therapeutics, Inc.	Eosinophilic Asthma, Asthma; Eosinophilic, Asthma	03/27	05/27
EXHALE-3, NCT05813288: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma	Recruiting	3	930	Europe, Japan, US, RoW	Dexpramipexole Dihydrochloride, Placebo	Areteia Therapeutics	Eosinophilic Asthma, Asthma; Eosinophilic, Asthma	12/26	02/27
2019-003013-34: Targeting severe asthma sub-types with a view to reducing worsening symptoms, improving asthma control, quality of life and lung function.	Not yet recruiting	2	234	Europe	Dexpramipexole, Vibrox, KNS-760704, Tablet, Capsule, Vibrox	University of Leicester, National Institute for Health Research, EME, Knopp Biosciences LLC	T2-High and T2-Low severe asthma, Sub-types of severe asthma, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
SUSPIRE-1, NCT06533553: A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD	Active, not recruiting	2	30	US	Dexpramipexole Dihydrochloride	Areteia Therapeutics	Chronic Obstructive Pulmonary Disease	10/25	12/25